3.5.3. disease management follow-up. prevention rutis includes counselling regarding avoidance risk factors, non-antimicrobial measures antimicrobial prophylaxis . interventions attempted order. urological risk factor must identified treated. significant residual urine treated optimally, including cic judged appropriate. 3.5.3.1. evidence summary broad literature cut-off 31st may 2021 identified 3,604 abstracts 361 selected full text review. total 114 systematic reviews guidelines based systematic literature searches 131 original publications selected analysis. 18 relevant publications identified references reviewed studies. selected studies assigned one nine subgroups based method prevention. updated search cut-off date 1st june 2022 identified 316 abstracts 25 selected analysis. evidence question addressed was: women recurrent symptomatic lower urinary tract infection interventions reduce rate recurrence? 3.5.3.2. behavioural modifications women ruti counselled avoidance risks (e.g., insufficient drinking, habitual post-coital delayed urination, wiping front back defecation, douching wearing occlusive underwear) initiation long-term prophylactic drug treatment, although limited evidence available regarding approaches . open-label rct found additional fluid intake 1.5 l day premenopausal women ruti low-volume drinkers (< 1.5 l day) reduced number cystitis episodes antibiotic usage 12-month period 3.5.3.3. non-antimicrobial prophylaxis 3.5.3.3.1. hormonal replacement based results four meta-analyses topical oestrogen therapy (either creme pessary) shows trend towards ruti prevention [150-153]. studies reported application superior compared placebo inferior compared antibiotics. due pharmacokinetics vaginal admission systematic side effects, however local irritation minor bleeding occur. use oral oestrogens effective ruti prophylaxis compared placebo, furthermore associated unfavourable systematic side effect profile. single prospective, non-comparative study 30 pre-menopausal women ruti oral contraceptives reported beneficial effect additional topical oestrogen therapy . 3.5.3.3.2. immunoactive prophylaxis several meta-analyses systematic reviews based nine rcts showed oral immunotherapy om-89 effective safe method prevention rutis compared placebo short-term follow (< 6 months) . vaginal suppository containing ten strains heat-killed uropathogenic bacteria significantly reduced risk ruti compared placebo meta-analysis three small rcts [155-157]. preventive effect pronounced booster treatment. systematic review two retrospective three prospective cohort studies concluded mv140 may decrease number ruti episodes and/or increase probability patients uti free . placebo controlled rct mv140 reported significant decrease ruti episodes mv140 groups vs. placebo . 12 months follow-up 25% women treated placebo (95% ci, 15% 35%) uti free compared 56% (95% ci, 44% 67%) 58% (95% ci, 44% 67%) women received three six months mv140 treatment, respectively. median number uti episodes per patient 3.0 (0.5 6.0) placebo group compared 0.0 (0.0 1.0) groups receiving mv140 . comparative single-centre study 124 women vaccinated strovac compared 49 women receiving antibiotic prophylaxis 24-month follow-up concluded strovac effective non-antibiotic prophylaxis ruti . however, study randomised blinded resulting high risk bias (selection imprecision). 3.5.3.3.3. prophylaxis probiotics (lactobacillus spp.) five meta-analyses differing results eleven relevant systematic reviews identified [151,161-174]. two meta-analyses reported significant positive effects ruti prevention effective probiotics compared placebo . contradictory results four meta-analyses result analysis different lactobacillus strains different administration regimes, treatment durations, patient populations. studies concluded lactobacillus strains effective vaginal flora restoration ruti prevention. highest efficacy shown l. rhamnosus gr-1, l. reuteri b-54, l. reuteri rc-14, l. casei shirota, l. crispatus ctv-05 . although meta-analyses including known lactobacilli strains show significant treatment benefit , sensitivity analysis excluding studies using ineffective strains resulted positive treatment effect . eleven systematic reviews, seven concluded prophylaxis vaginal probiotics beneficial clinical impact prevention ruti [152,153,161,164,166,168-171,173]. available data minimal low quality allow panel make recommendations route admission, optimal dosage, treatment duration probiotic prophylaxis. 3.5.3.3.4. prophylaxis cranberry seven meta-analyses several systematic reviews identified [151,175-180]. cochrane systematic review meta-analysis found compared placebo, water treatment, cranberry products significantly reduce occurrence symptomatic uti overall women recurrent utis . however, six subsequent meta-analyses concluded consumption cranberry-containing products may protect utis certain patient populations [151,176-180]. differing outcomes across meta-analyses contributed clinical methodological heterogeneity included studies . rct 145 women randomised high-dose vs. low-dose cranberry proanthocyanidin extract reported significant reduction number symptomatic uti episodes groups . although efficacy cranberry products remains unclear, panel consensus clinicians may recommend ruti prevention women informed weak evidence base due favourable benefit harm ratio. however, clear clinical evidence regarding appropriate dose treatment duration. 3.5.3.3.5. prophylaxis d-mannose meta-analysis including one rct, one randomised cross-over trial one prospective cohort study analysed data 390 patients found d-mannose effective ruti prevention compared placebo comparable efficacy antibiotic prophylaxis . another systematic review, concluded d-mannose significant effect uti, studies needed confirm findings . systematic review including 695 patients reported d-mannose improved quality life significantly reduced rutis catheter non-catheter users effective reducing incidence rutis prolonging uti-free periods . however, cochrane systematic review including 719 patients unable determine d-mannose compared treatment, supplements antibiotics significantly reduced number ruti episodes . overall quality evidence low. 3.5.3.3.6. endovesical instillation endovesical instillations hyaluronic acid (ha) chondroitin sulphate (cs) used glycosaminoglycan (gag) layer replenishment treatment interstitial cystitis, overactive bladder, radiation cystitis, prevention ruti . meta-analysis (n=143) based two rcts two non-rcts found significantly decreased uti rates per patient/year significantly longer mean uti recurrence times ha ha-cs therapy compared control treatment . addition, subgroup analysis two rcts using ha-cs reported significantly decreased uti rate per patient-year, significantly longer mean uti recurrence time significantly better pelvic pain urgency/frequency (puf) total score. however, 24-h urinary frequency measured number voids 3 days significantly improved therapy . another meta-analysis (n=800) including two rcts six non-rcts found compared control treatment ha, without cs, associated significantly lower mean uti rate per patient-year significantly longer time uti recurrence . furthermore, ha-cs therapy associated significantly greater mean reductions puf total symptom scores percentage patients uti recurrence follow-up also lower . randomised controlled studies available ha plus cs, quality evidence higher combination ha alone. 3.5.3.3.7. methenamine hippurate cochrane review 2012 based thirteen studies, high levels heterogeneity, concluded methenamine hippurate may effective preventing uti patients without renal tract abnormalities, particularly used short-term prophylaxis . meta-analysis 2021 based six studies found although studies showed trend towards benefit methenamine hippurate prevention rutis statistically significant difference efficacy methenamine hippurate comparators . subsequent rct including 240 women randomised (1 : 1) receive once-daily low-dose antibiotic prophylaxis twice-daily methenamine hippurate twelve months reported incident rate patient-reported symptomatic utis decreased 1.38 episodes per person per year methenamine hippurate group vs. 0.89 episodes per person per year antibiotic group. absolute difference 0.49 confirming methenamine hippurate inferior antibiotic prophylaxis. rate adverse events similar groups sustained benefit treatment arms observed six months follow-up . 3.5.3.4. antimicrobials preventing ruti 3.5.3.4.1. continuous low-dose antimicrobial prophylaxis post-coital prophylaxis four meta-analyses numerous systematic reviews guidelines identified [153,193-203]. available meta-analyses conclude antibiotic prophylaxis effective approach uti recurrences compared placebo treatment [193-195]. antimicrobials may given continuous low-dose prophylaxis longer periods, post-coital prophylaxis. significant difference efficacy two approaches. consensus optimal duration continuous antimicrobial prophylaxis, studies reporting treatment duration three twelve months. discontinuation drug, utis tend re-occur, especially among those, three infections annually. mandatory offer continuous low-dose antimicrobial post-coital prophylaxis counselling, behavioural modifications well non-antimicrobial measures unsuccessful. differences outcomes antibiotics reach statistical significance. choice agent based local resistance patterns. regimens include nitrofurantoin 50 mg 100 mg daily, fosfomycin trometamol 3 g every ten days, trimethoprim 100 mg daily pregnancy cephalexin 125 mg 250 mg cefaclor 250 mg daily . post-coital prophylaxis considered pregnant women history frequent utis onset pregnancy, reduce risk uti . 3.5.3.4.2. self-diagnosis self-treatment patients good compliance, self-diagnosis self-treatment short course regimen antimicrobial agent considered . choice antimicrobials sporadic acute uncomplicated uti (section 3.4.4.4).